Vivakor, Inc. annual report, Q4 FY2008

Vivakor, Inc. 10-K Summary (Fiscal Year Ended Dec 31, 2008)

Business Context and Reporting Period

Vivakor, Inc. is a transdisciplinary research company focused on molecular medicine, electro-optics, biological handling, and natural compounds. The reporting period covers the fiscal year ended December 31, 2008. The company transitioned from a limited liability company to a corporation in April 2008 and began significant operations in March 2008. In October 2008, Vivakor acquired approximately 84% of HealthAmerica, Inc., obtaining assets related to medical record bar coding and MRI software technology (SLICES). The company operates with a small team of six employees (four full-time, two part-time) as of year-end.

Key Financial Metrics

Metric20082007
Revenue$194,700$0
Net Loss$(1,028,460)$(20,500)
Accumulated Deficit$(1,048,960)$(20,500)
Cash and Cash Equivalents$145,669$0
Total Current Liabilities$2,410,617$20,500
Working Capital$(2,264,948)$(20,500)
Research & Development Expenses$443,107$0
Non-Cash Stock Compensation$339,102$0

Liquidity and Debt: The company holds $145,669 in cash against $2.41 million in current liabilities. Significant debt includes a $1,481,648 note payable incurred for the HealthAmerica acquisition and $343,331 in loans/advances from related parties. The company has not made all required scheduled payments on the acquisition note.

Material Changes vs. Prior Period

  • Revenue Generation: The company moved from zero revenue in 2007 to $194,700 in 2008, primarily from contract research services. Approximately 99% of this revenue came from a single related-party customer.
  • Acquisition Activity: The October 2008 acquisition of HealthAmerica assets resulted in the capitalization of $3.71 million in patents and a $1.5 million note payable. This transaction also triggered a $339,102 non-cash stock compensation expense.
  • Expense Growth: Operating expenses surged from $20,500 in 2007 to $1.23 million in 2008 due to the commencement of R&D activities, payroll, and the acquisition-related costs.
  • Capital Structure: The company converted from an LLC to a corporation and issued significant common stock, including shares used to pay for the HealthAmerica acquisition.

Guidance, Outlook, Risks, and Unusual Items

Going Concern: The independent auditors have expressed substantial doubt about the company's ability to continue as a going concern due to a lack of working capital and an accumulated deficit. The company states it does not have sufficient cash to fund operations for the next twelve months.

Financing Status: A public offering (Form S-1) filed in late 2008 to raise up to $3.45 million was terminated in April 2009 after failing to receive payment on subscription agreements. The company has no firm commitments for future funding.

Product Outlook: Sales of cryovials and antioxidant supplements (VivaBlend) commenced in 2009. However, the company expects to remain unprofitable in the short term and relies on external financing, grants, or strategic partnerships to continue development.

Risks: Key risks include the inability to raise capital, the early-stage nature of all product candidates, reliance on a single customer for revenue, and the potential obsolescence of acquired HealthAmerica technology.

Investor Verification Checklist

  • Capital Adequacy: Verify the company's current cash runway and any new financing agreements entered into post-filing, given the terminated 2008 offering.
  • Debt Compliance: Confirm the status of the $1.48 million HealthAmerica acquisition note, specifically whether the company is current on payments or if the debt has been restructured.
  • Revenue Concentration: Assess the sustainability of revenue streams given that 99% of 2008 revenue came from a related party.
  • Patent Viability: Review the commercial potential and regulatory status of the acquired HealthAmerica MRI technology and the company's own pipeline, noting that 13 provisional patents expired due to lack of funds.
  • Related Party Transactions: Scrutinize the terms of loans and advances from officers and shareholders, which total over $340,000.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.